Danaher Corp. Positioned as a Beneficiary of Biotech Sector Recovery
Danaher Corp. (DHR) is emerging as a strong investment in the biotech sector as funding begins to stabilize after a four-year downturn. The company is forecasting 3%–6% revenue growth, assuming a gradual recovery in biotech spending. Danaher's valuation is currently below its historical upper range, making it an attractive play for investors.
Tickers: $DHR
Topics: Biotech Funding Capital Markets Danaher Corp Market Recovery